EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL.

Exclusion Criteria

• •Major systemic illness (cardiac, respiratory, renal, hepatic and gastrointestinal system).
• •Severe anemia, leucopenia or thrombocytopenia.
• •Pregnant and breastfeeding females.
• •Hypersensitivity /intolerance to Roflumilast or methotrexate.
• •Intake of systemic therapy for psoriasis within the last 3 Months.
• •Patients receiving any relevant topical treatment for at least 2 weeks before initiation of our study.
• •Erythrodermic, pustular psoriasis or psoriatic arthritis.
• •Patients with autoimmune diseases e.g., SLE.
• •Patients with solid or hematological malignancies e.g., breast cancer, leukemia, etc.
• •Patients on biological therapy within the last 6 months prior to recruitment.